April Research Update: Major Depressive Disorder

Slideshow

Relapse in MDD is associated with morphologic brain changes; stopping exercise may increase depressive symptoms; and inflammatory biomarkers may predict which treatment-resistant MDD patients benefit from ECT.

Related Videos
Experts on MDD.
Experts on MDD.
Related Content

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Blue Light, Depression, and Bipolar Disorder

August 4th 2021

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023

Psilocybin Plus SSRIs for Treatment-Resistant Major Depression

September 19th 2023

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Blue Light, Depression, and Bipolar Disorder

August 4th 2021

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023

Psilocybin Plus SSRIs for Treatment-Resistant Major Depression

September 19th 2023

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Non-Psychiatric Medications With Potential to Worsen Symptoms in Major Depression

September 25th 2023

Blue Light, Depression, and Bipolar Disorder

August 4th 2021

Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD

September 20th 2023

Psilocybin Plus SSRIs for Treatment-Resistant Major Depression

September 19th 2023
© 2023 MJH Life Sciences

All rights reserved.